Drug Profile
Research programme: RNAi therapeutics - Samyang/Takeda
Alternative Names: siRNA-PM - Samyang/TakedaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Samyang Group; Takeda
- Developer Takeda
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 20 Aug 2012 Preclinical trials in Cancer in Japan (Parenteral)